David J. Cennimo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
David J. Cennimo has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Helen Fernandes
Weill Cornell Medicine
1 shared publication - Jason Zucker
Division of Infectious Diseases, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA
1 shared publication - Kristin Wong
Internal Medicine-Pediatrics, Rutgers University New Jersey Medical School, Newark, USA
1 shared publication
Latest Publications
- 14 December 2023
- Published by Wolters Kluwer Health in Infectious Diseases in Clinical Practice
- Vol. 32 (1)
Lessons From the Mpox Education and Vaccination Campaign
- 14 December 2023
- Published by Wolters Kluwer Health in Infectious Diseases in Clinical Practice
- Vol. 32 (1)
Lessons From the Mpox Education and Vaccination Campaign
- Open Access
- 1 January 2016
- Published by Medknow in International Journal of Pediatrics and Adolescent Medicine
- Vol. 3 (3) , 103-108
Adolescent HIV viral load in an urban hospital in Newark, New Jersey
Background and objectives: Human immunodeficiency virus (HIV) in adolescents is a growing concern. Amid psychosocial challenges, adolescents must successfully transition into adult-centered care; however, little is known about outcome measurements within this period. We assessed the trend in adolescent HIV viral loads (VLs) in a community with a high HIV prevalence, allowing physicians to better recognize the challenges of transitioning adolescents with HIV to adult care. Patients and methods: All HIV RNA VLs from the Molecular Virology Lab at University Hospital in Newark, New Jersey, from 2007 to 2010 were obtained. Patients were divided into pediatric (25 years of age) age groups. Univariate and multivariate analyses assessed characteristics of patients by age and gender. Results: A minimum of 40 pediatric, 178 adolescent, and 1335 adult patients were identified per year. There was a statistically significant increase in VLs of adolescents when compared to pediatric patients (P < .02). In 3 of the 4 years, there was a statistically significant increase in the rate of male adolescents reaching undetectable VLs compared to female adolescents. The average VL by age demonstrated increasing VLs from age 12 through age 24, while the percentage of patients reaching undetectable VLs peaked at 80% at age 8 and declined through age 24. Conclusion: Successful transitional care programs should focus on pediatric needs to address the noticeable decrease in virologic control beginning at 8 years of age and the decreased rate of virologic suppression in females, creating concern for potential gender inequalities and increased risk of vertical transmission.
- 1 January 2016
- Published by Medknow in International Journal of Pediatrics and Adolescent Medicine
- Vol. 3 (3) , 103-108
Open AccessAdolescent HIV viral load in an urban hospital in Newark, New Jersey
Background and objectives: Human immunodeficiency virus (HIV) in adolescents is a growing concern. Amid psychosocial challenges, adolescents must successfully transition into adult-centered care; however, little is known about outcome measurements within this period. We assessed the trend in adolescent HIV viral loads (VLs) in a community with a high HIV prevalence, allowing physicians to better recognize the challenges of transitioning adolescents with HIV to adult care. Patients and methods: All HIV RNA VLs from the Molecular Virology Lab at University Hospital in Newark, New Jersey, from 2007 to 2010 were obtained. Patients were divided into pediatric (25 years of age) age groups. Univariate and multivariate analyses assessed characteristics of patients by age and gender. Results: A minimum of 40 pediatric, 178 adolescent, and 1335 adult patients were identified per year. There was a statistically significant increase in VLs of adolescents when compared to pediatric patients (P < .02). In 3 of the 4 years, there was a statistically significant increase in the rate of male adolescents reaching undetectable VLs compared to female adolescents. The average VL by age demonstrated increasing VLs from age 12 through age 24, while the percentage of patients reaching undetectable VLs peaked at 80% at age 8 and declined through age 24. Conclusion: Successful transitional care programs should focus on pediatric needs to address the noticeable decrease in virologic control beginning at 8 years of age and the decreased rate of virologic suppression in females, creating concern for potential gender inequalities and increased risk of vertical transmission.